Epstein Secrets

Brazil 10.25% 2028 @ 103 (ytm 9.78%) Paul Paul Barrett I Managing Director I Global Investment Opportunities Group I J.P. Morgan Securities LLC I J.P. Morgan Private Bank I J.P. Morgan Chase Bank N.A. 320 Park Avenue, le Floor, New York, NY 10022 NOT AN OFFICIAL CONFIRMATION: For informational purposes only. This rep

ytm 9.78%) Paul Paul Barrett I Managing Director I Global Investment Opportunities Group I J.P. Morgan Securities LLC I J.P. Morgan Private Bank I J.P. Morgan Chase Bank N.A. 320 Park Avenue, le Floor, New York, NY 10022 NOT AN OFFICIAL CONFIRMATION: For informational purposes only. This report does not represent an offi

1) holds an Australian Financial Services Licence No. 238367. It is subject to the supervision of the Australian Prudential Regulation Authority and the Australian Securities and Investments Commission. J.P. Morgan Securities LLC is a V.S. registered broker-dealer incorporated in Delaware, U.S.A. (ABRN #109293610) This

USD denominated so no explicit FX risk Paul Paul Barrett I Managing Director I Global Investment Opportunities Group I M. Morgan Securities LLC I M. Morgan Private Bank I M. Morgan Chase Bank M. NOT AN OFFICIAL CONFIRMATION: For informational purposes only. This report does not represent an official account of the

copy of the "Characteristics and Risks of Standardized Options" booklet, please contact your JPMorgan Advisor. For clients domiciled in Australia,. Morgan Chase Bank, (ABN 43 074 112 011) holds an Australian Financial Services Licence No. 238367. It is subject to the supervision of the Australian Prudential Regu

1) holds an Australian Financial Services Licence No. 238367. It is subject to the supervision of the Australian Prudential Regulation Authority and the Australian Securities and Investments Commission.. Morgan Securities LLC is a U.S. registered broker-dealer incorporated in Delaware, U.S.A. (ABRN 4109293610) This emai

invested Slim at a valuation of 5204m. Other investors in the round included Kleiner Perkins, Google Ventures, Roche and Labcorp. In September 2013, J.P. Morgan and Goldman Sachs led the IPO of Foundation Medicine. As of 240, January 2014, Foundation Medicine had a market capitalization of 5900m. 23andme 2

es not, contain all the information which would be required in an Australian prospectus or product disclosure statement. It has not been lodged with the Australian Securities and Investments Commission. As a prospectus or product disclosure statement is not required to be prepared or lodged with the Australian Securitie